Intestinal Inflammation and Parkinson's Disease

Area of Science:

• Neuroscience
• Gastroenterology
• Immunology

Background:

• Parkinson's disease (PD) is a prevalent neurodegenerative disorder impacting patient quality of life.
• The protein alpha-synuclein is implicated in PD pathogenesis, with Braak's hypothesis suggesting intestinal origins and spread via the vagus nerve.
• Abnormal alpha-synuclein expression and gut inflammation are observed in inflammatory bowel disease (IBD), hinting at a potential connection to PD.

Purpose of the Study:

• To review current research on the relationship between intestinal inflammation and Parkinson's disease.
• To elucidate the mechanisms linking gut inflammation and PD, including the role of alpha-synuclein.
• To explore the potential of intestinal dysfunction and the gut microbiome as therapeutic targets for PD.

Main Methods:

• Literature review of studies investigating intestinal inflammation, gut dysbiosis, and Parkinson's disease.
• Analysis of proposed mechanisms connecting inflammatory bowel disease (IBD) and PD.
• Examination of alpha-synuclein pathology in the context of intestinal health.

Main Results:

• Intestinal inflammation and dysbiosis are increasingly recognized as factors in PD development.
• Potential links between IBD and PD include shared genetic factors, inflammatory pathways, altered intestinal permeability, and gut microbiome imbalances.
• Constipation and other intestinal dysfunctions are recognized as non-motor symptoms of PD.

Conclusions:

• While the exact starting point of PD remains unconfirmed, intestinal dysfunction can influence the central nervous system, affecting alpha-synuclein pathology and systemic inflammation.
• Targeting intestinal inflammation and modulating the gut microbiome represent promising avenues for novel diagnostic and therapeutic strategies for Parkinson's disease.